"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...

In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...

Jake Leach, Dexcom CEO, joins 'Closing Bell Overtime' to talk its 2026 outlook, the impact of GLP-1s, new devices and more.

Supermodels, singers, and diabetics are all wearing it. Jake Leach, Dexcom CEO, says these sensors are the future.

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...

DexCom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, ...

Dexcom convinced a federal judge that its phrasing about market share in two statements about sales growth for certain ...

In addition to Canaccord Genuity, Dexcom also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on the same day, Barclays reiterated a Sell rating on Dexcom (NASDAQ: ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...

Some of medtech's most innovative technologies were on display at the Consumer Electronics Show (CES) in Las Vegas this week.

This resulted in seven deaths and multiple injuries to various people, again, because of the inaccuracy in a specific set of ...